Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome

Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome

We have identified a novel ω-hydroxy-alkanedicarboxylic acid, ESP 55016, that favorably alters serum lipid variables in obese female Zucker (fa/fa) rats. ESP 55016 reduced serum non-HDL-cholesterol (non-HDL-C), triglyceride, and nonesterified fatty acid levels while increasing serum HDL-C and β-hydr...

Full description

Bibliographic Details
Main Authors: Clay T. Cramer, Brian Goetz, Krista L.M. Hopson, Gregory J. Fici, Rose M. Ackermann, Stephen C. Brown, Charles L. Bisgaier, W.G. Rajeswaran, Daniela C. Oniciu, Michael E. Pape
Format: Article
Language:English
Published: Elsevier 2004-07-01
Series:Journal of Lipid Research
Subjects:
hepatocytes
acetyl-CoA carboxylase
Zucker
AMP-activated protein kinase
xenobiotic-CoA
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520317855

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520317855

Similar Items